COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 990: Articles 9891-9900  | Next

Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection
Li, W., Syed, F., Yu, R. X., Yang, J., Xia, Y., Relich, R. F., Zhang, S., Khalili, M., Huang, L., Kacena, M. A., Zheng, X., Yu, Q.
10.1101/2021.12.22.21268218 — Posted: 2021-12-30
mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Cancer Patients
Zeng, C., Evans, J. P., Chakravarthy, K., Qu, P., Reisinger, S., Song, N. j., Rubinstein, M., Shields, P. G., Li, Z., Liu, S.-L.
10.1101/2021.12.28.21268398 — Posted: 2021-12-30
SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1α/XBP1 ER stress pathway in human lung-derived cells
Nguyen, L. C., Renner, D. M., Silva, D., Yang, D., Medina, K. M., Nicolaescu, V., Gula, H., Drayman, N., Valdespino, A., Mohamed, A., Dann, C., Wannemo, K., Robinson-Mailman, L., Gonzalez, A., Stock, L., Cao, M., Qiao, Z., Moellering, R. E., Tay, S., Randall, G., Beers, M. F., Rosner, M. R., Oakes, S. A., Weiss, S. R.
10.1101/2021.12.30.474519 — Posted: 2021-12-30
Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication
Lan, S., Tedbury, P. R., Ong, Y. T., Shah, R., Slack, R. L., Cilento, M. E., Zhang, H., Du, H., Lulkin, N., Le, U. Q., Kirby, K. A., Melcak, I., Cantara, W. A., Boggs, E. A., Sarafianos, S. G.
10.1101/2021.12.29.474471 — Posted: 2021-12-30
Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
Teng, I.-T., Nazzari, A. F., Choe, M., Liu, T., Oliveira de Souza, M., Petrova, Y., Tsybovsky, Y., Wang, S., Zhang, B., Artamonov, M., Madan, B., Huang, A., Lopez Acevedo, S. N., Pan, X., Ruckwardt, T. J., DeKosky, B. J., Mascola, J. R., Misasi, J., Sullivan, N., Zhou, T., Kwong, P. D.
10.1101/2021.12.29.474491 — Posted: 2021-12-30
Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals.
De Marco, L., D'Orso, S., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Capone, A., Sabatini, A., Guerrera, G., Placido, R., Sambucci, M., Angelini, D. F., Giannessi, F., Picozza, M., Caltagirone, C., Salvia, A., Volpe, E., Balice, M. P., Rossini, A., Rotzschke, O., Giardina, E., Battistini, L., Borsellino, G.
10.1101/2021.12.30.474453 — Posted: 2021-12-30
Unsupervised genome-wide cluster analysis: nucleotide sequences of the omicron variant of SARS-CoV-2 are similar to sequences from early 2020
Hahn, G., Lee, S., Prokopenko, D., Novak, T., Hecker, J., Khurana, S., Baden, L. R., Randolph, A. G., Weiss, S. T., Lange, C.
10.1101/2021.12.29.474469 — Posted: 2021-12-30
Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscape
Gayvert, K., Copin, R., McKay, S., Setliff, I., Lim, W. K., Baum, A., Kyratsous, C. A., Atwal, G. S.
10.1101/2021.12.30.474516 — Posted: 2021-12-30
Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R., Hubbard, S. R., Mulligan, M. J., Landau, N. R.
10.1101/2021.12.28.474369 — Posted: 2021-12-30
Pipeline for retrieval of COVID-19 immune signatures
Newton, A. J. H., Chartash, D., Kleinstein, S. H., McDougal, R. A.
10.1101/2021.12.29.474353 — Posted: 2021-12-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).